Bing-Huan Lin

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2”.

Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2

Biomedicine & Pharmacotherapy(2024)10.1016/j.biopha.2024.117542

N/A

0DataRank · unranked

6 citations

Yen-Ching Li, Megumi Murakami, Yu‐Shan Wu, Yang-Hui Huang, Tai‐Ho Hung +3 more

Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2

European Journal of Pharmacology(2024)10.1016/j.ejphar.2024.177231

N/A

0DataRank · unranked

3 citations

Bing-Huan Lin, Megumi Murakami, Yu‐Shan Wu, Tai‐Ho Hung, Suresh V. Ambudkar +2 more

The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs

European Journal of Pharmaceutical Sciences(2025)10.1016/j.ejps.2025.107337

N/A

0DataRank · unranked

0 citations

Bing-Huan Lin, Megumi Murakami, Yu‐Shan Wu, Tai‐Ho Hung, Suresh V. Ambudkar +2 more